CHEPLAPHARM GMBH ANNOUNCES SUCCESSFUL PRICING OF TERM LOAN B
Greifswald, 11 February 2022

Cheplapharm is proud to announce today that it has signed a new term loan facility of €1,480 million. The proceeds from the new term loan facility will be used to roll the Company's existing €980 million term loan facility in full and for general corporate puposes including future acquisitions. The new TLB bears interest at a rate of EURIBOR plus initially 4.0% p.a. and has a maturity of seven years. Cheplapharm also entered into a new revolving credit facility of €545 million, a significant increase over the existing revolving credit facility of €450 million.

Commenting on the successful transaction, Jens Rothstein, CFO, said: "We are very pleased with the continued demand and investor confidence in the Cheplapharm business model and our growth strategy. Thanks to the new credit facilities at very attractive rates, we now have the necessary flexibility and liquidity to further develop the company"

About CHEPLAPHARM

CHEPLAPHARM is a fast-growing pharmaceutical company in Europe, headquartered in Greifswald, Germany, offering branded and niche products in approximately 145 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ presse(at)cheplapharm.com

Forward-looking Statements
This news release may include "forward-looking statements" within the meaning of the securities laws of certain applicable jurisdictions. These forward-looking statements include, but are not limited to, all statements other than statements of historical facts contained in this news release, including, without limitation, those regarding Cheplapharm's intentions, beliefs or current expectations concerning, among other things: Cheplapharm's future financial conditions and performance, results of operations and liquidity; Cheplapharm's strategy, plans, objectives, prospects, growth, goals and targets; future developments in the markets in which Cheplapharm participates or is seeking to participate; and anticipated regulatory changes in the industry in which Cheplapharm operates. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "anticipate", "believe", "continue", "ongoing", "estimate", "expect", "intend", "may", "plan", "potential", "predict", "project", "target", "seek" or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward-looking statements are not guarantees of future performance and that Cheplapharm's actual financial condition, results of operations and cash flows, and the development of the industry in which Cheplapharm operates, may differ materially from (and be more negative).